Abstract:Human papillomaviruses (HPVs) contribute to approximately 5% of all human cancers. Species-specific barriers limit the ability to study HPV pathogenesis in animal models. Murine papillomavirus (MmuPV1) provides a powerful tool to study the roles of papillomavirus genes in pathogenesis arising from a natural infection. We previously identified Protein Tyrosine Phosphatase Non-Receptor Type 14 (PTPN14), a tumor suppressor targeted by HPV E7 proteins, as a putative cellular target of MmuPV1 E7. Here, we confirmed the MmuPV1 E7-PTPN14 interaction. Based on the published structure of the HPV18 E7/PTPN14 complex, we generated a MmuPV1 E7 mutant, E7 K81S , that was defective for binding PTPN14. Wild-type (WT) and E7 K81S mutant viral genomes replicated as extrachromosomal circular DNAs to comparable levels in mouse keratinocytes. E7 K81S mutant virus (E7 K81S MmuPV1) was generated and used to infect FoxN/Nude mice. E7 K81S MmuPV1 caused neoplastic lesions at a frequency similar to that of WT MmuPV1, but the lesions arose later and were smaller than WT-induced lesions. The E7 K81S MmuPV1-induced lesions also had a trend towards a less severe grade of neoplastic disease. In the lesions, E7 K81S MmuPV1 supported the late (productive) stage of the viral life cycle and promoted E2F activity and cellular DNA synthesis in suprabasal epithelial cells to similar degrees as WT MmuPV1. There was a similar frequency of lateral spread of infections among mice infected with E7 K81S or WT MmuPV1. Compared to WT MmuPV1-induced lesions, E7 K81S MmuPV1-induced lesions had a significant expansion of cells expressing differentiation markers, Keratin 10 and Involucrin. We conclude that an intact PTPN14 binding site is necessary for MmuPV1 E7's ability to contribute to papillomavirus-induced pathogenesis and this correlates with MmuPV1 E7 causing a delay in epithelial differentiation, which is a hallmark of papillomavirus-induced neoplasia. Human papillomaviruses cause human cancers largely through virally encoded E6 and E7 oncogenes. A murine papillomavirus, MmuPV1, causes lesions in laboratory mice that mimic features of human papillomavirus-induced lesions including cancer. In this study, we investigated how the interaction of MmuPV1 E7 with the cellular tumor suppressor protein, PTPN14, contributes to viral pathogenesis using a MmuPV1 E7 mutant defective for interacting with PTPN14, E7 K81S . We examined phenotypic differences between the E7 K81S and wild type MmuPV1 in tissue culture and in mice. The E7 K81S mutant genome was able to replicate as a nuclear plasmid in tissue culture. In vivo, E7 K81S mutant virus caused dysplastic lesions like wild type virus; however, they were smaller in size, arose later, and trended towards being less severe in their grade of neoplastic disease. The E7 K81S -induced lesions showed evidence for increased E2F activation and reprogramming of suprabasal cells to support DNA synthesis similar to that seen in lesions induced by wild type virus. One clear molecular difference was that the E7 K81S -induced lesions showed an expansion of cells expressing differentiation markers. Our study shows that an intact PTPN14 binding site is important for MmuPV1 E7's ability to contribute to MmuPV1-induced skin disease.

BRAF Inhibition and UVB Light Synergistically Promote Mus musculus Papillomavirus 1-Induced Skin Tumorigenesis

Mtorc1/autophagy-Regulated MerTK in Mutant BRAFV600 Melanoma with Acquired Resistance to BRAF Inhibition

VCAM-1 Upregulation Contributes to Insensitivity of Vemurafenib in BRAF-Mutant Thyroid Cancer.

Immune Status, Strain Background, and Anatomic Site of Inoculation Affect Mouse Papillomavirus (MmuPV1) Induction of Exophytic Papillomas or Endophytic Trichoblastomas

Data from Loss of ARF Sensitizes Transgenic BRAF<sup>V600E</sup> Mice to UV-Induced Melanoma via Suppression of XPC

MmuPV1 E7's interaction with PTPN14 delays Epithelial differentiation and contributes to virus-induced skin disease

Stress keratin 17 enhances papillomavirus infection-induced disease by downregulating T cell recruitment

Efficacy of Vemurafenib in a Heavy Smoker with BRAF-mutated Lung Adenocarcinoma: A Case Report and Literature Review.

Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase Activation and Upregulation of Proapoptotic Bcl-2 Proteins

Loss Of Arf Sensitizes Transgenic Braf(V600e) Mice To Uv-Induced Melanoma Via Suppression Of Xpc

Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.

A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience

Loss of Lkb1 cooperates with BrafV600E and ultraviolet radiation, increasing melanoma multiplicity and neural-like dedifferentiation.

Real-world use and outcomes of targeted therapy and immunotherapy for adjuvant treatment of BRAF-mutated melanoma patients in the United States

Dual MAPK Inhibition Triggers Pro-inflammatory Signals and Sensitizes BRAF V600E Glioma to T Cell-Mediated Checkpoint Therapy

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer

Abstract 1548: Ultraviolet B-induced platelet-activating factor receptor agonists mediate augmentation of melanoma tumor growth via regulatory T cells: Implication of systemic immunosuppression

Anticancer Effects of Combinational Treatment with BRAFV600E Sirna and PI3K Pathway Inhibitors in Melanoma Cell Lines Harboring BRAFV600E.

UVB-Induced Microvesicle Particle Release and Its Effects on the Cutaneous Microenvironment

BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms

Supplementary Figure 1 from Loss of ARF Sensitizes Transgenic BRAF<sup>V600E</sup> Mice to UV-Induced Melanoma via Suppression of XPC